High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective

Regulatory Toxicology and Pharmacology

Volumn 54, Issue 3, 2009, Pages 301-307

  Buckley, Lorrene A ^a   Dorato, Michael A ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Department of Molecular and Anatomical Imaging   (United States)

Author keywords

Clinical relevance; Drug safety; Limit dose; Maximum Feasible Dose; Maximum Tolerated Dose

Indexed keywords

ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT;

ARTICLE; BIOASSAY; CARCINOGEN TESTING; DOSE CALCULATION; DRUG CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; HUMAN; LIVER HYPERTROPHY; MAXIMUM TOLERATED DOSE; METHODOLOGY; MULTIPLE DRUG DOSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TOXICITY TESTING; TOXICOLOGY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

EID: 67650251227     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2009.05.015     Document Type: Article

References (34)

1. Apostolou A., and Helton E.D. Maximum dosage level in testing low-toxicity chemicals for carcinogenicity in rodents. J. Appl. Toxicol. 13 3 (1993) 209-212
2. Attarchi F. Exploratory IND studies: a review of Food and Drug Administration Guidance and similar provision in Europe. Drug Inf. J. 41 (2007) 309-314
3. Barlow S.M., Greig J.B., Bridges J.W., Carere A., Carpy A.J.M., Galli C.L., Kleiner J., Knudsen I., Koeter H.B.W.M., Levy L.S., Madsen C., Mayer S., Narbonne J.F., Pfannkuch F., Prodanchuk M.G., Smith M.R., and Steinberg P. Hazard identification by methods of animal-based toxicology. Food Chem. Toxicol. 40 (2002) 145-191
4. Buckley L.A., Benson K., Davis-Bruno K., Dempster M., Finch G.L., Harlow P., Haggerty H.G., Hart T., Kinter L., Leighton J.K., McNulty J., Roskos L., Saber H., Stauber A., and Tabrizi M. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop. Intl. J. Toxicol. 27 4 (2008) 303-312
5. CHMP, 1987. Rules Governing Medicinal Products in the European Community, Vol. III. As referenced in ICH S1C(R2) 2008.
6. CPMP/SWP/372/01, 2001. Points to consider document on the nonclinical assessment of the carcinogenic potential of insulin analogues. Available from: .
7. CPMP/SWP/2600/01, 2002. Points to consider on the need for assessment of reproductive toxicity of human insulin analogues. Available from: .
8. CHMP/SWP/488313/2007, 2008. Guideline on repeated dose toxicity (Draft). Available from: .
9. Contrera J.F., Matthews E.J., Kruhlak N.L., and Benz R.D. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Reg. Toxicol. Pharmacol. 40 (2004) 185-206
10. Cutler N.R., Sramek J.J., Greenblatt D.J., Chaikin P., Ford N., Lesko L.J., Davis B., and Williams R.L. Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives. J. Clin. Pharmacol. 37 (1997) 767-783
11. Doe J.E., Boobis A.R., Blacker A., Dellarco V., Doerrer N.G., Franklin C., Goodman J.I., Kronenberg J.M., Lewis R., McConnell E.E., Marcier T., Moretto A., Nolan C., and Padilla S. A tiered approach to systemic toxicity testing for agricultural chemical safety assessment. Crit. Rev. Toxicol. 36 1 (2006) 37-68
12. Dorato M.A., and Engelhardt J.A. The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s). Reg. Toxicol. Pharmacol. 42 (2005) 265-274
13. Dorato, M.A., Buckley, L.A., 2006. Toxicology in the drug discovery and development process. In: Current Protocols in Pharmacology, vol. 10, no. 3. John Wiley and Sons Press, pp. 1-35.
14. Dorato M.A., McMillian C.L., and Vodicnik M.J. The toxicologic assessment of pharmaceutical and biotechnology products. In: Wallace Hayes A. (Ed). Principles and Methods of Toxicology. fifth ed. (2008), CRC Press 325-367
15. Goldstein B.D. Risk assessment methodology: maximum tolerated dose and two-stage carcinogenesis models. Toxicol. Pathol. 22 2 (1994) 194-197
16. Haseman J.K. Issues in carcinogenicity testing: dose selection. Fundam. Appl. Toxicol. 5 (1985) 66-78
17. Hess R. Repeated dose toxicity; industry perspective. In: D'Arcy P.F., and Harron D.W.G. (Eds). First International Conference on Harmonization (1991), Brussels, Belgium 197
18. Huff, J., Bucher, J.R., Schwetz, B.A., Barrett, J.C., 1994. Optimum exposure levels for chemical carcinogenesis experiments: concepts, principles, guidelines, and experience. Toxicologist. SOT Abstract 475.
19. ICH Topic M3(R2), 2008. Maintenance of the ICH Guideline on nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals. ICH Harmonized Tripartite Guideline.
20. ICH Topic S1C(R2), 2008. Dose selection for carcinogenicity studies of pharmaceuticals. ICH Harmonized Tripartite Guideline.
21. ILSI. The selection of doses in chronic toxicity/carcinogenicity studies. In: Grice H.C. (Ed). Current Issues in Toxicology (1984), Springer-Verlag 9-49
22. Kociba R.J. Issues in biochemical applications to risk assessment. How should the MTD be selected for chronic bioassays?. Environ. Health Perspect. 76 (1987) 169-174
23. Lewis R.W., Billington R., Debryune E., Gamer A., Lang B., and Carpanini F. Recognition of adverse and non-adverse effects in toxicity studies. Toxicol. Pathol. 30 1 (2002) 66-74
24. MHLW, 1985. Toxicity test guideline for pharmaceuticals, Japan Ministry of Health and Welfare. pp. 127 (Chapter 5). As referenced in ICH S1C(R2) 2008.
25. Mehendale H.M. Injury and repair as opposing forces in risk assessment. Toxicol. Lett. 82/83 (1995) 891-899
26. Morrow P.E., Haseman J.K., Hobbs C.H., Driscoll K.E., Vu V., and Oberdorster G. The maximum tolerated dose for inhalation bioassays: toxicity vs overload. Fundam. Appl. Toxicol. 29 (1996) 155-167
27. National Toxicology Program, 1984. Report of the NTP Ad-hoc Panel on Chemical Carcinogenesis Testing and Evaluation, DHHS, Washington DC.
28. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., and Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg. Toxicol. Pharmacol. 32 (2000) 56-67
29. Sontag, J.M., Page, N.P., Saffioti, U., 1976. Guidelines for Carcinogen Bioassay in Small Rodents. DHHS Publication (NIH) No. 76-801, National Cancer Institute, Bethesda, MD.
30. Stevens J.T. Risk assessment of pesticides. In: Williams, and Hottendorf (Eds). Comprehensive Toxicology: Toxicological Testing and Evaluation (1997), Pergamon 22
31. Tammara V., and Jacobson-Kram D. Exploratory investigational new drug (IND) studies in humans. Clin. Res. Regul. Aff. 24 2-4 (2007) 77-86
32. USFDA, 2005. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for Industry. Available from: .
33. USFDA, 2006. Exploratory IND studies. Guidance for Industry, Investigators, and Reviewers.
34. US Interagency Staff Group (ISG) on Carcinogens. Chemical Carcinogens: a review of the science and its associated principles. Environ. Health Perspect. 67 (1986) 201-208